{"transactions":[{"id":719816,"issuer":{"id":6045,"kind":"organization","name":"Lineage Cell Therapeutics, Inc."},"owners":[{"id":33405,"kind":"person","name":"Mulroy Michael H.","position":1,"cik":"0001509725","reported_name":"Mulroy Michael H.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-07-02T21:00:38.000Z","date":"2026-07-01","kind":"grant","planned":false,"acquired":true,"shares":125000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Will vest and become exercisable on the earlier of July 1, 2027 and the date of the issuer's next annual meeting of shareholders, subject in any case to the reporting person's continuous service with the issuer."}],"balance_after":125000,"derivative":{"exercise_price":1.3,"expiration_date":"2036-07-01","underlying":"Common Shares","underlying_shares":125000},"source":{"system":"sec-edgar","filing":"0001193125-26-294871","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/876343/000119312526294871/ownership.xml","form_type":"4"}},{"id":1096706,"issuer":{"id":6045,"kind":"organization","name":"Lineage Cell Therapeutics, Inc."},"owners":[{"id":33405,"kind":"person","name":"Mulroy Michael H.","position":1,"cik":"0001509725","reported_name":"Mulroy Michael H.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-07-03T01:00:06.000Z","date":"2025-07-01","kind":"grant","planned":false,"acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Will vest and become exercisable on the earlier of July 1, 2026 and the date of the issuer's next annual meeting of shareholders, subject in any case to the reporting person's continuous service with the issuer."}],"balance_after":75000,"derivative":{"exercise_price":0.8977,"expiration_date":"2035-07-01","underlying":"Common Shares","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0000950170-25-093467","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/876343/000095017025093467/ownership.xml","form_type":"4"}},{"id":1353358,"issuer":{"id":6045,"kind":"organization","name":"Lineage Cell Therapeutics, Inc."},"owners":[{"id":33405,"kind":"person","name":"Mulroy Michael H.","position":1,"cik":"0001509725","reported_name":"Mulroy Michael H.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2024-11-25T21:30:03.000Z","date":"2024-11-22","kind":"purchase","planned":false,"acquired":true,"shares":40000,"price":0.566,"value":22640.0,"ownership":{"direct":true},"balance_after":298555,"source":{"system":"sec-edgar","filing":"0000950170-24-130592","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/876343/000095017024130592/ownership.xml","form_type":"4"}},{"id":1461371,"issuer":{"id":6045,"kind":"organization","name":"Lineage Cell Therapeutics, Inc."},"owners":[{"id":33405,"kind":"person","name":"Mulroy Michael H.","position":1,"cik":"0001509725","reported_name":"Mulroy Michael H.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-07-03T21:00:10.000Z","date":"2024-07-01","kind":"grant","planned":false,"acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Will vest and become exercisable on July 1, 2025, subject to the reporting person's continuous service with the issuer."}],"balance_after":75000,"derivative":{"exercise_price":0.9541,"expiration_date":"2034-07-01","underlying":"Common Shares","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0000950170-24-081607","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/876343/000095017024081607/ownership.xml","form_type":"4"}},{"id":1840353,"issuer":{"id":6045,"kind":"organization","name":"Lineage Cell Therapeutics, Inc."},"owners":[{"id":33405,"kind":"person","name":"Mulroy Michael H.","position":1,"cik":"0001509725","reported_name":"Mulroy Michael H.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-07-03T21:46:13.000Z","date":"2023-07-01","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Will vest and become exercisable on July 1, 2024, subject to the reporting person's continuous service with the issuer."}],"balance_after":50000,"derivative":{"exercise_price":1.41,"expiration_date":"2033-07-01","underlying":"Common Shares","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001493152-23-023347","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/876343/000149315223023347/ownership.xml","form_type":"4"}},{"id":2213193,"issuer":{"id":6045,"kind":"organization","name":"Lineage Cell Therapeutics, Inc."},"owners":[{"id":33405,"kind":"person","name":"Mulroy Michael H.","position":1,"cik":"0001509725","reported_name":"Mulroy Michael H.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-07-06T20:15:50.000Z","date":"2022-07-01","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Will vest and become exercisable on July 1, 2023, subject to the reporting person's continuous service with the issuer."}],"balance_after":50000,"derivative":{"exercise_price":1.57,"expiration_date":"2032-07-01","underlying":"Common Shares","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001493152-22-018682","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/876343/000149315222018682/ownership.xml","form_type":"4"}},{"id":2318221,"issuer":{"id":6045,"kind":"organization","name":"Lineage Cell Therapeutics, Inc."},"owners":[{"id":33405,"kind":"person","name":"Mulroy Michael H.","position":1,"cik":"0001509725","reported_name":"Mulroy Michael H.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares, no par value","published_at":"2022-03-25T20:15:22.000Z","date":"2022-03-24","kind":"purchase","acquired":true,"shares":7000,"price":1.4,"value":9800.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported is a weighted average. The shares were purchased in multiple transactions at prices ranging from not less than $1.40 to not more than $1.41. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within such range."}],"balance_after":258555,"source":{"system":"sec-edgar","filing":"0001493152-22-007754","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/876343/000149315222007754/ownership.xml","form_type":"4"}},{"id":2648696,"issuer":{"id":6045,"kind":"organization","name":"Lineage Cell Therapeutics, Inc."},"owners":[{"id":33405,"kind":"person","name":"Mulroy Michael H.","position":1,"cik":"0001509725","reported_name":"Mulroy Michael H.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-07-01T22:19:27.000Z","date":"2021-07-01","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Will vest and become exercisable on July 1, 2022, subject to the reporting person's continuous service with the issuer."}],"balance_after":50000,"derivative":{"exercise_price":2.86,"expiration_date":"2031-07-01","underlying":"Common Shares","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001493152-21-015882","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/876343/000149315221015882/ownership.xml","form_type":"4"}},{"id":2662200,"issuer":{"id":6045,"kind":"organization","name":"Lineage Cell Therapeutics, Inc."},"owners":[{"id":33405,"kind":"person","name":"Mulroy Michael H.","position":1,"cik":"0001509725","reported_name":"Mulroy Michael H.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-06-21T20:15:44.000Z","date":"2021-06-18","kind":"exercise","acquired":false,"shares":24720,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option became exercisable in four equal quarterly installments after the date of grant on July 1, 2016."}],"balance_after":0,"derivative":{"exercise_price":2.2,"expiration_date":"2021-06-30","underlying":"Common Shares","underlying_shares":24720},"source":{"system":"sec-edgar","filing":"0001493152-21-014860","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/876343/000149315221014860/ownership.xml","form_type":"4"}},{"id":2662199,"issuer":{"id":6045,"kind":"organization","name":"Lineage Cell Therapeutics, Inc."},"owners":[{"id":33405,"kind":"person","name":"Mulroy Michael H.","position":1,"cik":"0001509725","reported_name":"Mulroy Michael H.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares, no par value","published_at":"2021-06-21T20:15:44.000Z","date":"2021-06-18","kind":"exercise","acquired":true,"shares":24720,"price":2.2,"value":54384.0,"ownership":{"direct":true},"balance_after":251555,"source":{"system":"sec-edgar","filing":"0001493152-21-014860","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/876343/000149315221014860/ownership.xml","form_type":"4"}},{"id":3093738,"issuer":{"id":6045,"kind":"organization","name":"Lineage Cell Therapeutics, Inc."},"owners":[{"id":33405,"kind":"person","name":"Mulroy Michael H.","position":1,"cik":"0001509725","reported_name":"Mulroy Michael H.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-07-02T21:04:24.000Z","date":"2020-07-01","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Will become exercisable on July 1, 2021, based upon continued service on the board of directors."}],"balance_after":40000,"derivative":{"exercise_price":0.8263,"expiration_date":"2030-07-01","underlying":"Common Shares","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001493152-20-012539","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/876343/000149315220012539/ownership.xml","form_type":"4"}},{"id":3469445,"issuer":{"id":6045,"kind":"organization","name":"Lineage Cell Therapeutics, Inc."},"owners":[{"id":33405,"kind":"person","name":"Mulroy Michael H.","position":1,"cik":"0001509725","reported_name":"Mulroy Michael H.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-07-04T01:12:21.000Z","date":"2019-07-01","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Will become exercisable on June 30, 2020, based upon continued service on the board of directors."}],"balance_after":40000,"derivative":{"exercise_price":1.03,"expiration_date":"2029-06-30","underlying":"Common Shares","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001209191-19-041306","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/876343/000120919119041306/doc4.xml","form_type":"4"}},{"id":3594307,"issuer":{"id":6045,"kind":"organization","name":"Lineage Cell Therapeutics, Inc."},"owners":[{"id":33405,"kind":"person","name":"Mulroy Michael H.","position":1,"cik":"0001509725","reported_name":"Mulroy Michael H.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares, no par value","published_at":"2019-03-15T20:49:05.000Z","date":"2019-03-08","kind":"grant","acquired":true,"shares":194271,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Acquired pursuant to that certain Agreement and Plan of Merger, dated November 7, 2018 (the \"Merger Agreement\"), by and between the Issuer, Patrick Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of the Issuer, and Asterias Biotherapeutics, Inc., a Delaware corporation (\"Asterias\").  Pursuant to the Merger Agreement, each share of Series A common stock of Asterias was converted into the right to receive 0.71 common shares of the Issuer."},{"field":"shares","element":"transactionShares","label":"F1","text":"Acquired pursuant to that certain Agreement and Plan of Merger, dated November 7, 2018 (the \"Merger Agreement\"), by and between the Issuer, Patrick Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of the Issuer, and Asterias Biotherapeutics, Inc., a Delaware corporation (\"Asterias\").  Pursuant to the Merger Agreement, each share of Series A common stock of Asterias was converted into the right to receive 0.71 common shares of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Acquired pursuant to that certain Agreement and Plan of Merger, dated November 7, 2018 (the \"Merger Agreement\"), by and between the Issuer, Patrick Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of the Issuer, and Asterias Biotherapeutics, Inc., a Delaware corporation (\"Asterias\").  Pursuant to the Merger Agreement, each share of Series A common stock of Asterias was converted into the right to receive 0.71 common shares of the Issuer."}],"balance_after":226821,"source":{"system":"sec-edgar","filing":"0001209191-19-019722","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/876343/000120919119019722/doc4.xml","form_type":"4"}},{"id":3597262,"issuer":{"id":9581,"kind":"organization","name":"Serina Therapeutics, Inc."},"owners":[{"id":33405,"kind":"person","name":"Mulroy Michael H.","position":1,"cik":"0001509725","reported_name":"Mulroy Michael H.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Common Stock","published_at":"2019-03-14T01:03:18.000Z","date":"2019-03-11","kind":"grant","acquired":true,"shares":65000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Options will become exercisable in four equal quarterly installments from the date of grant on March 11, 2019 provided that the grantee remains a director on the last day of the applicable calendar quarter."}],"balance_after":65000,"derivative":{"exercise_price":4.28,"expiration_date":"2029-03-10","underlying":"Common Stock","underlying_shares":65000},"source":{"system":"sec-edgar","filing":"0001209191-19-019313","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1708599/000120919119019313/doc4.xml","form_type":"4"}},{"id":3610864,"issuer":{"id":159180,"kind":"organization","name":"Asterias Biotherapeutics, Inc.","symbol":"NONE"},"owners":[{"id":33405,"kind":"person","name":"Mulroy Michael H.","position":1,"cik":"0001509725","reported_name":"Mulroy Michael H.","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2019-03-05T21:31:26.000Z","date":"2019-03-01","kind":"tax_withholding","acquired":false,"shares":76588,"price":0.95,"value":72758.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the grant of shares reported herein."}],"balance_after":273622,"source":{"system":"sec-edgar","filing":"0001140361-19-004431","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1509725/000114036119004431/form4.xml","form_type":"4"}},{"id":3610863,"issuer":{"id":159180,"kind":"organization","name":"Asterias Biotherapeutics, Inc.","symbol":"NONE"},"owners":[{"id":33405,"kind":"person","name":"Mulroy Michael H.","position":1,"cik":"0001509725","reported_name":"Mulroy Michael H.","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2019-03-05T21:31:26.000Z","date":"2019-03-01","kind":"grant","acquired":true,"shares":252606,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares reported herein were awarded to the Reporting Person by the Issuer's Board of Directors upon recommendation by the Compensation Committee, in connection with  the Company's 2018 bonus payment to the Reporting Person, in lieu of cash payment to the Reporting Person."}],"balance_after":350210,"source":{"system":"sec-edgar","filing":"0001140361-19-004431","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1509725/000114036119004431/form4.xml","form_type":"4"}},{"id":3830244,"issuer":{"id":159180,"kind":"organization","name":"Asterias Biotherapeutics, Inc.","symbol":"NONE"},"owners":[{"id":33405,"kind":"person","name":"Mulroy Michael H.","position":1,"cik":"0001509725","reported_name":"Mulroy Michael H.","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2018-08-29T12:02:07.000Z","date":"2018-08-27","kind":"purchase","acquired":true,"shares":3141,"price":1.5918,"value":4999.8438,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares were purchased in multiple trades at prices ranging from $1.575 to $1.60. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. The shares of common stock reported herein were purchased via a 10b5-1 plan established by the Reporting Person on August 16, 2017."}],"balance_after":97604,"source":{"system":"sec-edgar","filing":"0001140361-18-037213","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1509725/000114036118037213/form4.xml","form_type":"4"}},{"id":3859793,"issuer":{"id":159180,"kind":"organization","name":"Asterias Biotherapeutics, Inc.","symbol":"NONE"},"owners":[{"id":33405,"kind":"person","name":"Mulroy Michael H.","position":1,"cik":"0001509725","reported_name":"Mulroy Michael H.","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2018-07-27T20:00:19.000Z","date":"2018-07-25","kind":"purchase","acquired":true,"shares":2950,"price":1.6949,"value":4999.955,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares were purchased in multiple trades at prices ranging from $1.675 to $1.70. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. The shares of common stock reported herein were purchased via a 10b5-1 plan established by the Reporting Person on August 16, 2017, under which the Reporting Person is dedicating approximately 25 percent of his monthly after-tax salary to the purchase of Asterias common stock."}],"balance_after":94463,"source":{"system":"sec-edgar","filing":"0001140361-18-033875","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1509725/000114036118033875/form4.xml","form_type":"4"}},{"id":3877046,"issuer":{"id":6045,"kind":"organization","name":"Lineage Cell Therapeutics, Inc."},"owners":[{"id":33405,"kind":"person","name":"Mulroy Michael H.","position":1,"cik":"0001509725","reported_name":"Mulroy Michael H.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Common Shares","published_at":"2018-07-03T22:22:53.000Z","date":"2018-07-01","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Will become exercisable on June 30, 2019, based upon continued service on the board of directors."}],"balance_after":40000,"derivative":{"exercise_price":2.06,"expiration_date":"2023-06-30","underlying":"Common Shares","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001209191-18-041303","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/876343/000120919118041303/doc4.xml","form_type":"4"}},{"id":3882045,"issuer":{"id":159180,"kind":"organization","name":"Asterias Biotherapeutics, Inc.","symbol":"NONE"},"owners":[{"id":33405,"kind":"person","name":"Mulroy Michael H.","position":1,"cik":"0001509725","reported_name":"Mulroy Michael H.","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2018-06-27T11:03:56.000Z","date":"2018-06-25","kind":"purchase","acquired":true,"shares":3067,"price":1.63,"value":4999.21,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares were purchased in multiple trades at prices ranging from $1.60 to $1.707. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. The shares of common stock reported herein were purchased via a 10b5-1 plan established by the Reporting Person on August 16, 2017, under which the Reporting Person is dedicating approximately 25 percent of his monthly after-tax salary to the purchase of Asterias common stock."}],"balance_after":91513,"source":{"system":"sec-edgar","filing":"0001140361-18-030023","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1509725/000114036118030023/form4.xml","form_type":"4"}},{"id":3912055,"issuer":{"id":159180,"kind":"organization","name":"Asterias Biotherapeutics, Inc.","symbol":"NONE"},"owners":[{"id":33405,"kind":"person","name":"Mulroy Michael H.","position":1,"cik":"0001509725","reported_name":"Mulroy Michael H.","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2018-05-31T21:00:34.000Z","date":"2018-05-25","kind":"purchase","acquired":true,"shares":3153,"price":1.5857,"value":4999.7121,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares were purchased in multiple trades at prices ranging from $1.575 to $1.60. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. The shares of common stock reported herein were purchased via a 10b5-1 plan established by the Reporting Person on August 16, 2017, under which the Reporting Person is dedicating approximately 25 percent of his monthly after-tax salary to the purchase of Asterias common stock."}],"balance_after":88446,"source":{"system":"sec-edgar","filing":"0001140361-18-026566","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1509725/000114036118026566/form4.xml","form_type":"4"}},{"id":3954750,"issuer":{"id":159180,"kind":"organization","name":"Asterias Biotherapeutics, Inc.","symbol":"NONE"},"owners":[{"id":33405,"kind":"person","name":"Mulroy Michael H.","position":1,"cik":"0001509725","reported_name":"Mulroy Michael H.","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2018-04-27T20:33:54.000Z","date":"2018-04-25","kind":"purchase","acquired":true,"shares":3752,"price":1.33,"value":4990.16,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares were purchased in multiple trades at prices ranging from $1.275 to $1.45. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. The shares of common stock reported herein were purchased via a 10b5-1 plan established by the Reporting Person on August 16, 2017, under which the Reporting Person is dedicating approximately 25 percent of his monthly after-tax salary to the purchase of Asterias common stock."}],"balance_after":85293,"source":{"system":"sec-edgar","filing":"0001140361-18-020186","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1509725/000114036118020186/form4.xml","form_type":"4"}},{"id":3980690,"issuer":{"id":159180,"kind":"organization","name":"Asterias Biotherapeutics, Inc.","symbol":"NONE"},"owners":[{"id":33405,"kind":"person","name":"Mulroy Michael H.","position":1,"cik":"0001509725","reported_name":"Mulroy Michael H.","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2018-03-28T21:00:34.000Z","date":"2018-03-26","kind":"purchase","acquired":true,"shares":2839,"price":1.76,"value":4996.64,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares were purchased in multiple trades at prices ranging from $1.75 to $1.80. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. The shares of common stock reported herein were purchased via a 10b5-1 plan established by the Reporting Person on August 16, 2017, under which the Reporting Person is dedicating approximately 25 percent of his monthly after-tax salary to the purchase of Asterias common stock."}],"balance_after":81541,"source":{"system":"sec-edgar","filing":"0001140361-18-015535","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1509725/000114036118015535/form4.xml","form_type":"4"}},{"id":3988946,"issuer":{"id":159180,"kind":"organization","name":"Asterias Biotherapeutics, Inc.","symbol":"NONE"},"owners":[{"id":33405,"kind":"person","name":"Mulroy Michael H.","position":1,"cik":"0001509725","reported_name":"Mulroy Michael H.","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Stock Options","published_at":"2018-03-19T23:03:53.000Z","date":"2018-03-15","kind":"grant","acquired":true,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Subject to Mr. Mulroy's continued employment with the Company, 25% of the granted stock options vest on the first anniversary of the grant date, and the remaining 75% of the stock options in equal monthly installments over 36 months commencing after the first anniversary of the grant date.  The grant date of these options was March 14, 2018.  The stock options are exercisable upon vesting."}],"balance_after":200000,"derivative":{"exercise_price":1.95,"expiration_date":"2028-03-14","underlying":"Common Stock","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0001140361-18-014136","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1509725/000114036118014136/form4.xml","form_type":"4"}},{"id":3988945,"issuer":{"id":159180,"kind":"organization","name":"Asterias Biotherapeutics, Inc.","symbol":"NONE"},"owners":[{"id":33405,"kind":"person","name":"Mulroy Michael H.","position":1,"cik":"0001509725","reported_name":"Mulroy Michael H.","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2018-03-19T23:03:53.000Z","date":"2018-03-15","kind":"tax_withholding","acquired":false,"shares":28358,"price":1.95,"value":55298.1,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the grant of 94,782 shares of restricted stock, which is reported herewith on this Form 4."}],"balance_after":78702,"source":{"system":"sec-edgar","filing":"0001140361-18-014136","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1509725/000114036118014136/form4.xml","form_type":"4"}},{"id":3988944,"issuer":{"id":159180,"kind":"organization","name":"Asterias Biotherapeutics, Inc.","symbol":"NONE"},"owners":[{"id":33405,"kind":"person","name":"Mulroy Michael H.","position":1,"cik":"0001509725","reported_name":"Mulroy Michael H.","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2018-03-19T23:03:53.000Z","date":"2018-03-15","kind":"grant","acquired":true,"shares":94872,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":107060,"source":{"system":"sec-edgar","filing":"0001140361-18-014136","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1509725/000114036118014136/form4.xml","form_type":"4"}},{"id":4026601,"issuer":{"id":159180,"kind":"organization","name":"Asterias Biotherapeutics, Inc.","symbol":"NONE"},"owners":[{"id":33405,"kind":"person","name":"Mulroy Michael H.","position":1,"cik":"0001509725","reported_name":"Mulroy Michael H.","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2018-02-28T21:21:30.000Z","date":"2018-02-26","kind":"purchase","acquired":true,"shares":2255,"price":2.2172,"value":4999.786,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares were purchased in multiple trades at prices ranging from $2.175 to $2.225.  The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. The shares of common stock reported herein were purchased via a 10b5-1 plan established by the Reporting Person on August 16, 2017, under which the Reporting Person is dedicating approximately 25 percent of his monthly after-tax salary to the purchase of Asterias common stock."}],"balance_after":12188,"source":{"system":"sec-edgar","filing":"0001140361-18-010811","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1509725/000114036118010811/form4.xml","form_type":"4"}},{"id":4087922,"issuer":{"id":159180,"kind":"organization","name":"Asterias Biotherapeutics, Inc.","symbol":"NONE"},"owners":[{"id":33405,"kind":"person","name":"Mulroy Michael H.","position":1,"cik":"0001509725","reported_name":"Mulroy Michael H.","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2018-01-26T21:01:32.000Z","date":"2018-01-25","kind":"purchase","acquired":true,"shares":2134,"price":2.343,"value":4999.962,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares were purchased in multiple trades at prices ranging from $2.325 to $2.35.  The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. The shares of common stock reported herein were purchased via a 10b5-1 plan established by the Reporting Person on August 16, 2017, under which the Reporting Person is dedicating approximately 25 percent of his monthly after-tax salary to the purchase of Asterias common stock."}],"balance_after":9933,"source":{"system":"sec-edgar","filing":"0001140361-18-003400","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1509725/000114036118003400/form4.xml","form_type":"4"}},{"id":4119981,"issuer":{"id":159180,"kind":"organization","name":"Asterias Biotherapeutics, Inc.","symbol":"NONE"},"owners":[{"id":33405,"kind":"person","name":"Mulroy Michael H.","position":1,"cik":"0001509725","reported_name":"Mulroy Michael H.","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2017-12-29T00:41:45.000Z","date":"2017-12-26","kind":"purchase","acquired":true,"shares":2247,"price":2.22,"value":4988.34,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares were purchased in multiple trades at prices ranging from $2.15 to $2.25. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The shares of common stock reported herein were purchased via a 10b5-1 plan established by the Reporting Person on August 16, 2017, under which the Reporting Person is dedicating approximately 25 percent of his monthly after-tax salary to the purchase of Asterias common stock."}],"balance_after":7799,"source":{"system":"sec-edgar","filing":"0001140361-17-047667","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1509725/000114036117047667/form4.xml","form_type":"4"}},{"id":4148734,"issuer":{"id":159180,"kind":"organization","name":"Asterias Biotherapeutics, Inc.","symbol":"NONE"},"owners":[{"id":33405,"kind":"person","name":"Mulroy Michael H.","position":1,"cik":"0001509725","reported_name":"Mulroy Michael H.","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2017-11-29T21:01:00.000Z","date":"2017-11-27","kind":"purchase","acquired":true,"shares":2076,"price":2.41,"value":5003.16,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares were purchased in multiple trades at prices ranging from $2.35 to $2.45.  The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The shares of common stock reported herein were purchased via a 10b5-1 plan established by the Reporting Person on August 16, 2017, under which the Reporting Person is dedicating approximately 25 percent of his monthly after-tax salary to the purchase of Asterias common stock."}],"balance_after":5552,"source":{"system":"sec-edgar","filing":"0001140361-17-044157","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1509725/000114036117044157/form4.xml","form_type":"4"}},{"id":4179303,"issuer":{"id":159180,"kind":"organization","name":"Asterias Biotherapeutics, Inc.","symbol":"NONE"},"owners":[{"id":33405,"kind":"person","name":"Mulroy Michael H.","position":1,"cik":"0001509725","reported_name":"Mulroy Michael H.","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2017-10-27T20:00:19.000Z","date":"2017-10-25","kind":"purchase","acquired":true,"shares":1939,"price":2.55,"value":4944.45,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares were purchased in multiple trades at prices ranging from $2.525 to $2.60.  The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The shares of common stock reported herein were purchased via a 10b5-1 plan established by the Reporting Person on August 16, 2017, under which the Reporting Person is dedicating approximately 25 percent of his monthly after-tax salary to the purchase of Asterias common stock."}],"balance_after":3476,"source":{"system":"sec-edgar","filing":"0001140361-17-039812","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1509725/000114036117039812/form4.xml","form_type":"4"}},{"id":4200678,"issuer":{"id":159180,"kind":"organization","name":"Asterias Biotherapeutics, Inc.","symbol":"NONE"},"owners":[{"id":33405,"kind":"person","name":"Mulroy Michael H.","position":1,"cik":"0001509725","reported_name":"Mulroy Michael H.","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2017-09-27T18:04:32.000Z","date":"2017-09-25","kind":"purchase","acquired":true,"shares":1537,"price":3.251,"value":4996.787,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares were purchased in multiple trades at prices ranging from $3.175 to $3.35.  The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The shares of common stock reported herein were purchased via a 10b5-1 plan established by the Reporting Person on August 16, 2017, under which the Reporting Person is dedicating approximately 25 percent of his monthly after-tax salary to the purchase of Asterias common stock."}],"balance_after":1537,"source":{"system":"sec-edgar","filing":"0001140361-17-036580","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1509725/000114036117036580/form4.xml","form_type":"4"}},{"id":4266115,"issuer":{"id":6045,"kind":"organization","name":"Lineage Cell Therapeutics, Inc."},"owners":[{"id":33405,"kind":"person","name":"Mulroy Michael H.","position":1,"cik":"0001509725","reported_name":"Mulroy Michael H.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Common Shares","published_at":"2017-07-05T23:46:37.000Z","date":"2017-07-01","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Will become exercisable in four equal quarterly installments after the date of grant on July 1, 2017 based upon continued service on the board of directors."}],"balance_after":20000,"derivative":{"exercise_price":3.15,"expiration_date":"2022-06-30","underlying":"Common Shares","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001209191-17-043774","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/876343/000120919117043774/doc4.xml","form_type":"4"}},{"id":4270923,"issuer":{"id":159180,"kind":"organization","name":"Asterias Biotherapeutics, Inc.","symbol":"NONE"},"owners":[{"id":33405,"kind":"person","name":"Mulroy Michael H.","position":1,"cik":"0001509725","reported_name":"Mulroy Michael H.","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Stock Options (right to buy)","published_at":"2017-06-28T20:02:30.000Z","date":"2017-06-26","kind":"grant","acquired":true,"shares":800000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to Mr. Mulroy's continued employment with the Company, the stock options vest in equal monthly installments over 48 months commencing on July 31, 2017.  The stock options are exercisable upon vesting."}],"balance_after":800000,"derivative":{"exercise_price":3.7,"expiration_date":"2027-06-26","underlying":"Common Stock","underlying_shares":800000},"source":{"system":"sec-edgar","filing":"0001140361-17-026470","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1509725/000114036117026470/form4.xml","form_type":"4"}}]}